Skip to main content

News & Updates

2026-04

Landmark Paper: Phase II AML clinical trial accepted in Nature Communications

Phase II trial evaluating Quizartinib plus Omacetaxine mepesuccinate in FLT3-ITD AML co-led by Dr. Cheuk-Him Man is published in Nature Communications.

2024-03

Dr. Cheuk-Him Man appointed Associate Professor & Yat-sen Scholar at SYSU

Dr. Cheuk-Him Man joins Sun Yat-sen University School of Medicine as Associate Professor & Ph.D. Supervisor, launching the MCH Laboratory.

2023-12

Major paper in Blood: PLK4 rewires epigenetics to silence cGAS-STING in AML

Revealing that PLK4 inhibition overcomes epigenetic suppression of the cGAS-STING innate immunity pathway in TP53-mutated AML.